Practical management of patients with myelofibrosis receiving ruxolitinib.

@article{Harrison2013PracticalMO,
  title={Practical management of patients with myelofibrosis receiving ruxolitinib.},
  author={Claire N Harrison and Ruben A. Mesa and David Ross and Adam J Mead and Clodagh Keohane and Jason Gotlib and Srdan Verstovsek},
  journal={Expert review of hematology},
  year={2013},
  volume={6 5},
  pages={511-23}
}
Myelofibrosis (MF) is characterized by bone marrow fibrosis, progressive anemia and extramedullary hematopoiesis, primarily manifested as splenomegaly. Patients also experience debilitating constitutional symptoms, including sequelae of splenomegaly, night sweats and fatigue. Ruxolitinib (INC424, INCB18424, Jakafi, Jakavi), a JAK1 and JAK2 inhibitor, was approved in November 2011 by the US FDA for the treatment of intermediate- or high-risk MF, and more recently in Europe and Canada for the… CONTINUE READING

9 Figures & Tables

Connections & Topics

Mentioned Connections BETA
Bone MarrowIs associated anatomic site ofPrimary Myelofibrosis
Myelofibrosis ( MF ) is characterized by bone marrow fibrosis , progressive anemia and extramedullary hematopoiesis , primarily manifested as splenomegaly .
Bone MarrowIs primary anatomic site of diseasePrimary Myelofibrosis
Myelofibrosis ( MF ) is characterized by bone marrow fibrosis , progressive anemia and extramedullary hematopoiesis , primarily manifested as splenomegaly .
Ruxolitinib ( INC424 , INCB18424 , Jakafi , Jakavi ) , a JAK1 and JAK2 inhibitor , was approved in November 2011 by the US FDA for the treatment of intermediate- or high - risk MF , and more recently in Europe and Canada for the treatment of MF - related splenomegaly or symptoms .
All Topics